What is relapsed platinum-sensitive ovarian cancer?

If your ovarian cancer has relapsed at least 6 months after first treatment with a platinum-containing chemotherapy regimen, then it is considered to be platinum-sensitive. The initial chemotherapy regimen for ovarian cancer usually includes the combination of platinum and taxane. Although 70 to 80 percent of women will achieve a complete remission with this first-line chemotherapy, the majority will have a recurrence of their ovarian cancer at some time in the future. Relapsed platinum-sensitive ovarian cancer can be treated as a chronic disease, and some patients may experience periods of relapse followed by periods of remission. The three major goals of care for women with relapsed platinum-sensitive ovarian cancer are maintaining stable disease, minimizing the side effects of treatment, and preserving a good quality of life.

 

Thank you for your interest in the FAR-131 study. At this time we are no longer recruiting patients for this study.